Sinus node dysfunction (SND) gets a clear endorsement for dual chamber (DDD) pacing with a class I indication, even in those without manifest AV conduction abnormalities.
The recent DANPACE trial is cited showing reduced incidence of atrial fibrillation and need for reoperation in the patients with SND getting dual chamber devices versus single chamber atrial devices.